What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? 'Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus'

Gut

Volumn 67, Issue 11, 2018, Pages 1916-1917

  Lemoine, Maud ^a   Tillmann, Hans L ^b,c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b EAST CAROLINA UNIVERSITY   (United States)

^c Gastroenterology and Hepatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIGEN DETECTION; DIAGNOSTIC ACCURACY; DISEASE BURDEN; HEPATITIS C; HEPATITIS C VIRUS; HIGH INCOME COUNTRY; HUMAN; INCIDENCE; LIMIT OF DETECTION; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; MORTALITY RATE; NONHUMAN; NOTE; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RNA DEGRADATION; RURAL AREA; SENSITIVITY AND SPECIFICITY; SUSTAINED VIROLOGIC RESPONSE; VIREMIA; VIRUS DETECTION; VIRUS LOAD; GENETICS; HEPACIVIRUS; POINT OF CARE SYSTEM;

HEPACIVIRUS; HEPATITIS C; HUMANS; POINT-OF-CARE SYSTEMS; RNA, VIRAL;

EID: 85049341777     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2018-316438     Document Type: Note

References (11)

1. (WHO) WHO. Towards the elimination of hepatitis B and C by 2030. 2016 http://wwwworldhepatitissummitorg/docs/default-source/default-document-library/2015/resources/towardselimination-dr-gottfried-hirnschallpdfsfvrsn=6 (accessed 23 Nov 2016).
2. WHO. Global hepatitis report,2017. http://apps.who.nt/iris/bitstream/10665/255016/1/9789241565455-eng.pdfua=1
3. Llibre A, Shimakawa Y, Mottez E, et al. Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut 2018.
4. WHO. WHO list of prequalified in vitro diagnostic products. 2017 http://www. who. int/diagnostics-laboratory/evaluations/PQ-list/en/
5. Mederacke I, Wedemeyer H, Ciesek S, et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009;46:210-5.
6. Chevaliez S, Soulier A, Poiteau L, et al. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clin Virol 2014;61:145-8.
7. Mohamed Z, Mbwambo J, Shimakawa Y, et al. Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania. J Int AIDS Soc 2017;20:21856.
8. Grebely J, Lamoury FMJ, Hajarizadeh B, et al. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: A cohort study. Lancet Gastroenterol Hepatol 2017;2:514-20.
9. Ticehurst JR, Hamzeh FM, Thomas DL. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol 2007;45:2426-33.
10. Uojima H, Murakami S, Nakatani S, et al. Late relapse after a sustained virologic response at 24 weeks after treatment with daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection with liver cirrhosis. Intern Med 2018;57:951-6.
11. Klag T, Dietz J, Werner CR, et al. Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy. J Hepatol 2017;66:862-3.